December 7, 2009, Updated September 24, 2012

Patients developed antibodies against swine flu virus H1N1 and other flu strains in the clinical trial of Israeli universal flu vaccine developer BiondVax Pharmaceuticals. BiondVax shares have been soaring since the positive flu vaccine report.

The vaccine caused antibody response against two flu classes: type A and type B, which include all flu strains that affect people. The company said that other universal flu vaccines under development protect only against type A flu strains.

According to Biondvax CEO Dr. Ron Babecoff, “… This vaccine will save the need to get vaccinated every year… “

The Phase I/II clinical trial of BiondVax’s second-generation universal (multimetric) flu vaccine was conducted on 60 people aged 18-49. The vaccine was found to be safe in all the dosages given. The trial was conducted at Sourasky Medical Center in Tel Aviv.

The Phase I/II clinical trial is the first of two trials that Biondvax is conducting. The second trial is on 60 people aged 55-75. The company expects results in the first quarter of 2010.

View the ISRAEL21c video about the development of the flu shot that could last for three to five years and protect you from all the world’s strains of flu.


Fighting for Israel's truth

We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month. 

Jason Harris

Jason Harris

Executive Director

Read more: